Therefore, other mechanisms may be responsible for the observed effects, such as the interruption of virus assembly and release from the infected cells because of Ltc 1 interaction with other viral or host cell proteins; however, this warrants additional studies. Conclusions The Ltc 1 peptide exhibited significant

inhibition of the dengue protease and virus replication in HepG2 cells. Therefore, Ltc1 may act as a lead structure for developing therapies against DENV. Acknowledgments This project was funded by the Ministry of Science, Technology and Innovation-Malaysia (ERGS grant ER016-2013A). References 1. Stevens AJ, Gahan ME, Mahalingam S, Keller PA: The medicinal chemistry Selleck Z VAD FMK of dengue fever. J Med Chem 2009, 52:7911–7926. 10.1021/jm900652e19739651CrossRefPubMed 2. Gulati S, Maheshwari A: Atypical manifestations of dengue. Trop Med Int Health 2007,12(9):1087–1095. 10.1111/j.1365-3156.2007.01891.x17875019CrossRefPubMed 3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, APR-246 Brownstein

JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI: The global distribution and burden of dengue. Nature 2013, 496:504–507. 10.1038/nature12060365199323563266CrossRefPubMedCentralPubMed HKI-272 cost 4. Beatty ME, Stone A, Fitzsimons DW, Hanna JN, Lam SK, Vong S, Guzman MG, Mendez-Galvan JF, Halstead SB, Letson GW: Best practices in dengue surveillance: a report from theAsia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis

2010,4(11):e890. 10.1371/journal.pntd.0000890298284221103381CrossRefPubMedCentralPubMed 5. Shepard RAS p21 protein activator 1 DS, Undurraga EA, Halasa YA: Economic and disease burdenof dengue in Southeast Asia. PLoS Negl Trop Dis 2013,7(2):e2055. 10.1371/journal.pntd.0002055357874823437406CrossRefPubMedCentralPubMed 6. Beasley DW: Recent advances in the molecular biology of West Nile virus. Curr Mol Med 2005, 5:835–850. 10.2174/15665240577496227216375717CrossRefPubMed 7. Lindenbach BD, Rice CM: Molecular biology of flaviviruses. Adv Virus Res 2003, 59:23–61. 14696326CrossRefPubMed 8. Fields B, Knipe D, Howley P, Chanock R, Melnick J, Monath T, Roizman B, Straus S: Field’s Virology. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 1996. 9. Perera R, Kuhn RJ: Structural proteomics of dengue virus. Curr Opin Microbiol 2008, 11:369–377. 10.1016/j.mib.2008.06.004258188818644250CrossRefPubMedCentralPubMed 10. Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, Vasudevan SG: Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res 2008, 80:94–101. 10.1016/j.antiviral.2008.07.00118674567CrossRefPubMed 11. Noble CG, Seh CC, Chao AT, Shi PY: Ligand-bound structures of the dengue virus protease reveal the active conformation.